Target intelligence / Profile preview

Podocin (NPHS2)

Target
NPHS2
Molecular classification
Other (Integral membrane protein), Band-7-stomatin family, Slit diaphragm structural protein
01

Overview

Podocin is an integral membrane protein of 383 amino acids encoded by the NPHS2 gene and is a critical structural component of the glomerular slit diaphragm in kidney podocytes[5][6][2][3][8]. It is a member of the band-7-stomatin protein family and features a hairpin-like transmembrane domain, with both the N- and C-termini in the cytoplasm[5][1][6]. Podocin oligomerizes in cholesterol- and sphingolipid-rich lipid rafts at the podocyte foot processes to assemble a multiprotein complex that forms the filtration slit. Its C-terminal region interacts with crucial slit diaphragm proteins such as nephrin, CD2AP, and NEPH1, anchoring the complex to the cytoskeleton and stabilizing the glomerular filtration barrier[2][3][4][1][7]. Mutations in podocin (NPHS2) lead to various forms of steroid-resistant nephrotic syndrome, particularly in children, because they disrupt the slit diaphragm’s integrity, causing massive proteinuria and progression to chronic kidney disease[5][3][8]. Podocin is currently not a therapeutic target for drugs, but NPHS2 mutations serve as genetic biomarkers for disease diagnosis and prognosis. Besides the kidney, restricted podocin expression has also been demonstrated in Sertoli cells of the testis, suggesting a possible role in the blood-testis barrier[3].

Other names
Nephrosis 2, idiopathic, steroid-resistant (podocin)NPHS2Nephrosis 2 protein
02

Biological functions

Filtration barrier maintenanceRenal slit diaphragm assemblyAnchor for membrane complex to cytoskeleton
03

Disease associations

Nephrotic syndrome (especially steroid-resistant forms)Focal segmental glomerulosclerosis (FSGS)Minimal change diseaseCongenital nephrotic syndrome
04

Safety considerations

Genetic deficiency causes loss of filtration barrier, resulting in proteinuria and nephrotic syndrome.No known safety concerns for direct pharmacological targeting as podocin is a structural and not a classic therapeutic target.
05

Biomarkers

Mutations in NPHS2 as diagnostic/prognostic markers for steroid-resistant nephrotic syndrome and related glomerular disorders

Beyond the preview

Go deeper on Podocin (NPHS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Podocin (NPHS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call